MET and non-small cell lung carcinoma: The 2019 National Comprehensive Cancer Network (NCCN) guidelines highly recommend testing of patients with NSCLC for EGFR and BRAF mutations; ALK, ROS1, and NTRK rearrangements; and programmed death-ligand 1 (PD-L1) expression levels; and recommends RET rearrangement; ERBB2 and MET mutations; MET amplifications [3].